Results 1 to 10 of about 5,242 (246)

Comparative effectiveness of disease-modifying therapies for highly active relapsing-remitting multiple sclerosis despite previous treatment – a systematic review and network meta-analysis [PDF]

BMC Neurology
Background Comparative assessments of all available disease-modifying therapies (DMTs) in patients with highly active relapsing-remitting multiple sclerosis (RRMS) are lacking, even though some of these DMTs are restricted to this MS subpopulation.
Michael Köhler, Friedemann Paul, Kirsten Janke, Sibylle Sturtz, Daniela Preukschat, Sabine Ostlender, Michaela Florina Kerekes, Thomas Kaiser   +7 more
doaj   +2 more sources

Acceptability of external control-arm use in nononcology health technology assessment submissions [PDF]

Journal of Comparative Effectiveness Research
Aim: This study assessed the acceptability of external control-arm (ECA) use in nononcology health technology assessment (HTA) submissions in Europe. Materials & methods: We conducted a sequential mixed method study to investigate the study objective ...
Kamal Kant Mangla, Spyros Kolovos, Ana Lisica, Max Schlueter, Nick Fabrin Nielsen   +4 more
doaj   +2 more sources

A scoping review of the use of minimally important difference of EQ-5D utility index and EQ-VAS scores in health technology assessment [PDF]

Health and Quality of Life Outcomes
Objectives Estimates of minimally important differences (MID) can assist interpretation of data collected using patient-reported outcomes (PRO), but variability exists in the emphasis placed on MIDs in health technology assessment (HTA) guidelines.
Caroline Shaw, Louise Longworth, Bryan Bennett, Louise McEntee-Richardson, James W. Shaw   +4 more
doaj   +2 more sources

Single-fraction stereotactic radiosurgery versus microsurgical resection for the treatment of vestibular schwannoma: a systematic review and meta-analysis

Systematic Reviews, 2022
Background Vestibular schwannomas are benign tumours for which various treatments are available. We performed a systematic review of prospective controlled trials comparing the patient-relevant benefits and harms of single-fraction stereotactic ...
Thomas Jakubeit, Sibylle Sturtz, Dorothea Sow, Wolfram Groß, Christoph Mosch, Mattea Patt, Vera Weingärtner, Jan Boström, Roland Goldbrunner, Martina Markes   +9 more
doaj   +1 more source

Negative pressure wound therapy in patients with wounds healing by secondary intention: a systematic review and meta-analysis of randomised controlled trials

Systematic Reviews, 2020
Background Negative pressure wound therapy (NPWT) is a widely used method of wound treatment. We performed a systematic review of randomised controlled trials (RCTs) comparing the patient-relevant benefits and harms of NPWT with standard wound therapy ...
Yvonne Zens, Michael Barth, Heiner C. Bucher, Katrin Dreck, Moritz Felsch, Wolfram Groß, Thomas Jaschinski, Heike Kölsch, Mandy Kromp, Inga Overesch, Stefan Sauerland, Sven Gregor   +11 more
doaj   +1 more source

A simulation study to compare different estimation approaches for network meta-analysis and corresponding methods to evaluate the consistency assumption

BMC Medical Research Methodology, 2020
Background Network meta-analysis (NMA) is becoming increasingly popular in systematic reviews and health technology assessments. However, there is still ambiguity concerning the properties of the estimation approaches as well as for the methods to ...
Corinna Kiefer, Sibylle Sturtz, Ralf Bender   +2 more
doaj   +1 more source

Performance of several types of beta-binomial models in comparison to standard approaches for meta-analyses with very few studies

BMC Medical Research Methodology, 2022
Background Meta-analyses are used to summarise the results of several studies on a specific research question. Standard methods for meta-analyses, namely inverse variance random effects models, have unfavourable properties if only very few (2 – 4 ...
Moritz Felsch, Lars Beckmann, Ralf Bender, Oliver Kuss, Guido Skipka, Tim Mathes   +5 more
doaj   +1 more source

Auswirkungen der neuen Dossieranforderungen

Monitor Versorgungsforschung, 2023
Bei Markteintritt oder Zulassungserweiterung eines neuen Arzneimittels sind pharmazeutische Unternehmer in Deutschland seit 2011 zur Einreichung eines AMNOG-Nutzendossiers beim G-BA verpflichtet.
Dr. rer. nat. Maria Katharina Schweitzer, Dr. rer. nat. Manuel Nico Dold, Dr. rer. nat. Astrid Genet, Klaus Gossens PhD, Dipl.-Math. Thomas Klein-Hessling, Nils Löffler MSc, Dr. phil. Matthias Rabel, Dr. PH Andrej Rasch, Jessica Schmelcher MSc, Dr. rer. nat. Sebastian Werner, Natalia Wolfram   +10 more
doaj   +1 more source

Real-world clinical practice in health technology assessment: state of the art for 2022

Реальная клиническая практика: данные и доказательства, 2023
The real-world data are used in drug authorization procedures, comparative efficacy and safety research, to make changes in the Summary of Product Characteristics, clinical recommendations.
A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin   +2 more
doaj   +1 more source

Analyse von Orphan-Drug-Verfahren in der frühen Nutzenbewertung: RCTs versus best-verfügbare vergleichende Evidenz

Monitor Versorgungsforschung, 2023
Zur Beurteilung der Wirksamkeit und Sicherheit eines neuen Wirkstoffes ist für die europäische Zulassungsbehörde (European Medicines Agency, EMA) die randomisierte kontrollierte Studie (RCT) der Goldstandard.
Dr. rer. nat. Gerrit Müller, Dr. rer. nat. Lena Fanter, Dipl.-Ges.oec. Julia Knierim   +2 more
doaj   +1 more source